American Bio Medica (OTCMKTS:ABMC) vs. Exagen (NASDAQ:XGN) Critical Contrast

American Bio Medica (OTCMKTS:ABMC) and Exagen (NASDAQ:XGN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

75.3% of Exagen shares are owned by institutional investors. 3.1% of American Bio Medica shares are owned by company insiders. Comparatively, 12.6% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for American Bio Medica and Exagen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
American Bio Medica	0	0	0	0	0.00
Exagen	1	0	8	0	2.78

Exagen has a consensus price target of $14.17, indicating a potential upside of 131.10%. Given Exagen’s stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than American Bio Medica.

Valuation and Earnings

This table compares American Bio Medica and Exagen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
American Bio Medica	$910,000.00	N/A	-$1.41 million	N/A	N/A
Exagen	$55.64 million	2.50	-$15.11 million	($0.92)	-6.66

American Bio Medica has higher earnings, but lower revenue than Exagen.

Profitability

This table compares American Bio Medica and Exagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
American Bio Medica	N/A	N/A	N/A
Exagen	-29.94%	-113.48%	-30.28%

Summary

Exagen beats American Bio Medica on 6 of the 10 factors compared between the two stocks.

About American Bio Medica

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.